Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice

Journal of Lipid Research

Volumn 48, Issue 7, 2007, Pages 1476-1487

  Qu, Shen ^a   Perdomo, German ^a   Su, Dongming ^a   D'Souza, Fiona M ^a   Shachter, Neil S ^b   Dong, H Henry ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b Columbia University ^*  (United States)

Author keywords

Apolipoprotein a v; Apolipoprotein c iii; High density lipoprotein; Hypertriglyceridemia; Lipoprotein metabolism; Very low density lipoprotein

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL METABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HYPERTRIGLYCERIDEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; CHOLESTEROL; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MICE; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; TRIGLYCERIDES;

EID: 34548171784     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600498-JLR200     Document Type: Conference Paper

References (43)

1. Rapp, R. J. 2002. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol. Rev. 10: 163-172.
2. Moller, D. E., and K. D. Kaufman. 2005. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56: 45-62.
3. Hopkins, P. N., G. Heiss, R. C. Ellison, M. A. Province, J. S. Pankow, J. H. Eckfeldt, and S. C. Hunt. 2003. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 108: 519-523.
4. Hopkins, P. N., L. L. Wu, S. C. Hunt, and E. A. Brinton. 2005. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J. Am. Coll. Cardiol. 45: 1003-1012.
5. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
6. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
7. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
8. Aouizerat, B. E., M. Kulkarni, D. Heilbron, D. Drown, S. Raskin, C. R. Pullinger, M. J. Malloy, and J. P. Kane. 2003. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J. Lipid Res. 44: 1167-1173.
9. Lai, C. Q., E. S. Tai, C. E. Tan, J. Cutter, S. K. Chew, Y. P. Zhu, X. Adiconis, and J. M. Ordovas. 2003. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J. Lipid Res. 44: 2365-2373.
10. Li, G. P., J. Y. Wang, S. K. Yan, B. S. Chen, H. Xue, and G. Wu. 2004. Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoprotein levels in a Chinese population. Clin. Genet. 65: 470-476.
11. Klos, K. L., S. Hamon, A. G. Clark, E. Boerwinkle, K. Liu, and C. F. Sing. 2005. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J. Lipid Res. 46: 564-571.
12. Wright, W. T., I. S. Young, D. P. Nicholls, C. Patterson, K. Lyttle, and C. A. Graham. 2006. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis. 185: 353-360.
13. Eichenbaum-Voline, S., M. Olivier, E. L. Jones, R. P. Naoumova, B. Jones, B. Gau, H. N. Patel, M. Seed, D. J. Betteridge, D. J. Galton, et al. 2004. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24: 167-174.
14. Mar, R., P. Pajukanta, H. Allayee, M. Groenendijk, G. Dallinga-Thie, R. M. Krauss, J. S. Sinsheimer, R. M. Cantor, T. W. de Bruin, and A. J. Lusis. 2004. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 94: 993-999.
15. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, and J. C. Cohen. 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
16. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
17. Aalto-Setala, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J. Lipid Res. 37: 1802-1811.
18. Ito, Y. N., A. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790-793.
19. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
20. Grosskopf, I., N. Baroukh, S. J. Lee, Y. Kamari, D. Harats, E. M. Rubin, L. A. Pennacchio, and A. D. Cooper. 2005. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 25: 2573-2579.
21. Fruchart-Najib, J., E. Bauge, L. S. Niculescu, T. Pham, B. Thomas, C. Rommens, Z. Majd, B. Brewer, L. A. Pennacchio, and J. C. Fruchart. 2004. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319: 397-404.
22. Baroukh, N., E. Bauge, J. Akiyama, J. Chang, V. Afzal, J. C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio. 2004. Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler. Thromb. Vasc. Biol. 24: 1297-1302.
23. Rensen, P. C., K. W. van Dijk, and L. M. Havekes. 2005. Apolipoprotein AV: low concentration, high impact. Arterioscler. Thromb. Vasc. Biol. 25: 2445-2447.
24. Jakel, H., M. Nowak, A. Helleboid-Chapman, J. Fruchart-Najib, and J. C. Fruchart. 2006. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann. Med. 38: 2-10.
25. Nakae, J., T. Kitamura, D. L. Silver, and D. Accili. 2001. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108: 1359-1367.
26. Altomonte, J., A. Richter, S. Harbaran, J. Suriawinata, J. Nakae, S. N. Thung, M. Meseck, D. Accili, and H. Dong. 2003. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am. J. Physiol. 285: E718-E728.
27. Dong, H., J. Altomonte, N. Morral, M. Meseck, S. N. Thung, and S. L. C. Woo. 2002. Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes. 51: 130-138.
28. Huard, J., H. Lochmüller, G. Acsadi, A. Jani, B. Massie, and G. Karpati. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2: 107-115.
29. Altomonte, J., L. Cong, S. Harbaran, A. Richter, J. Xu, M. Meseck, and H. H. Dong. 2004. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 114: 1493-1503.
30. O'Kane, M. J., G. B. Wisdom, J. McEneny, N. V. McFerran, and E. R. Trimble. 1992. Pre-beta high-density lipoprotein determined by immunoblotting with chemiluminescent detection. Clin. Chem. 38: 2273-2277.
31. de la Llera Moya, M., V. Atger, J. L. Paul, N. Fournier, N. Moatti, P. Giral, K. E. Friday, and G. Rothblat. 1994. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 14: 1056-1065.
32. Zannis, V. I., A. Chroni, and M. Krieger. 2006. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84: 276-294.
33. Huby, T., C. Doucet, C. Dachet, B. Ouzilleau, Y. Ueda, V. Afzal, E. Rubin, M. J. Chapman, and P. Lesnik. 2006. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J. Clin. Invest. 116: 2767-2776.
34. Chroni, A., T. J. Nieland, K. E. Kypreos, M. Krieger, and V. I. Zannis. 2005. SR-BI mediates cholesterol efflux via its interactions with lipid-bound apoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry. 44: 13132-13143.
35. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
36. Merkel, M., B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J. Biol. Chem. 280: 21553-21560.
37. Merkel, M., and J. Heeren. 2005. Give me A5 for lipoprotein hydrolysis! J. Clin. Invest. 115: 2694-2696.
38. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280: 25383-25387.
39. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein- triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
40. Koo, C., T. L. Innerarity, and R. W. Mahley. 1985. Obligatory role of cholesterol and apolipoprotein E in the formation of large cholesterol-enriched and receptor-active high density lipoproteins. J. Biol. Chem. 260: 11934-11943.
41. Mahley, R. W., Y. Huang, and K. H. Weisgraber. 2006. Putting cholesterol in its place: apoE and reverse cholesterol transport. J. Clin. Invest. 116: 1226-1229.
42. Brousseau, M. E., S. Santamarina-Fojo, B. L. Vaisman, D. Applebaum-Bowden, A. M. Berard, G. D. Talley, H. B. Brewer, Jr., and J. M. Hoeg. 1997. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. J. Lipid Res. 38: 2537-2547.
43. Berard, A. M., B. Foger, A. Remaley, R. Shamburek, B. L. Vaisman, G. Talley, B. Paigen, R. F. Hoyt, Jr., S. Marcovina, H. B. Brewer, Jr., et al. 1997. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3: 744-749.